ORPHA:98879
Hemophilia B
Also known as: Congenital F9 deficiency · Congenital factor IX deficiency · Christmas disease
Publications
10,499
97.1th percentile
Trials
120
Interventional, condition-specific
Researchers
1,057
Distinct authors in sample
Gene link
F9
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare hematological disorder characterized by spontaneous or prolonged hemorrhages due to factor IX deficiency.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010604
- MeSH:D002836
- OMIM:306900
- UMLS:C0008533
- NCIT:C26721
Additional Mondo synonyms (10)
congenital factor IX deficiency · congenital factor IX disorder · factor IX deficiency · haemophilia b, X-linked recessive · haemophilia type B · hemophilia B · hemophilia b, X-linked recessive · hemophilia type B · hereditary Factor IX deficiency · hereditary Factor IX deficiency disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — F9
- LiteraturePresent
10,499 matched papers (4,035 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
120 matched on ClinicalTrials.gov (18 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (F9).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
10,499
10,499 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
10,499 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
4,035 in the last 10 years · high confidence · 97.1th percentile (publications denominator)
Phrase hits: 10,499 · MeSH hits: 193
Who's working on it?
1,057
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Matino D7 papers · 2026
Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Papers in Europe PMC - 02Miesbach W7 papers · 2026
Department of Haemostaseology and Haemophilia, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.
Papers in Europe PMC - 03Mahlangu J6 papers · 2026
Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa.
Papers in Europe PMC - 04Yang R6 papers · 2026
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Papers in Europe PMC - 05Le Quellec S5 papers · 2026
CSL Behring Europe, Philipp-Reis-Strasse 2, 65795 Hattersheim am Main, Germany.
Papers in Europe PMC - 06Monahan PE5 papers · 2026
CSL Behring, 1020 First Avenue, King of Prussia, PA 61501, USA.
Papers in Europe PMC - 07Dai J4 papers · 2026
Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address: dj40572@rjh.com.cn.
Papers in Europe PMC - 08Dargaud Y4 papers · 2026
French Reference Center for Hemophilia, Clinical Hemostasis Unit, Hospital Louis Pardel, Lyon, France; UR4609, Research Unit on Haemostasis and Thrombosis, University Claude Bernard Lyon 1, Lyon, France. Electronic address: ydargaud@univ-lyon1.fr.
Papers in Europe PMC - 09Drelich D4 papers · 2026
CSL Behring, 1020 First Avenue, King of Prussia, PA 61501, USA.
Papers in Europe PMC - 10Hermans C4 papers · 2026
Division of Haematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
120
interventional trials for this specific condition
120 interventional trials matched this specific condition name; 18 currently recruiting in our sample. 369 trials are registered for hemophilia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
120 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.7th percentile).
high confidence · 98.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
120 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05611801·RECRUITING·A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Conditions: Hemophilia A · Hemophilia B·Matched via name + MeSH
- NCT05145127·RECRUITING·Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Conditions: Hemophilia A · Hemophilia B·Matched via name + MeSH
- NCT06003387·RECRUITING·Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Conditions: Hemophilia B·Matched via name + MeSH
- NCT05630651·RECRUITING·The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
Conditions: Hemophilia B·Matched via name + MeSH
- NCT06700096·RECRUITING·An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
Conditions: Hemophilia B·Matched via name + MeSH
- NCT06747416·NOT YET RECRUITING·KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
Conditions: Hemophilia a and B·Matched via name + MeSH
- NCT07080905·RECRUITING·Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Conditions: Hemophilia B·Matched via name + MeSH
- NCT05709288·RECRUITING·Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
Conditions: Hemophilia B·Matched via name + MeSH
- NCT05641610·RECRUITING·A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
Conditions: Hemophilia B·Matched via name + MeSH
- NCT06565481·RECRUITING·Measurement Properties in People with Hemophilia
Conditions: Hemophilia a · Hemophilia B · Musculoskeletal Complication · Measurement Error·Matched via name + MeSH
- NCT04647227·RECRUITING·SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Conditions: Hemophilia A With Inhibitor · Hemophilia B With Inhibitor·Matched via name + MeSH
- NCT07644832·RECRUITING·An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Conditions: Hemophilia A · Hemophilia B · Factor VII Deficiency·Matched via name + MeSH
- NCT06349473·RECRUITING·A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Conditions: Healthy Participants · Hemophilia A · Hemophilia B · Factor VII Deficiency·Matched via name + MeSH
- NCT05568719·RECRUITING·Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Conditions: Hemophilia A · Hemophilia B·Matched via name + MeSH
- NCT03961243·RECRUITING·Lentiviral FIX Gene Therapy
Conditions: Hemophilia B·Matched via name + MeSH
Broader category: hemophilia
369
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06816056·RECRUITING·Manual Therapy in Hemophilic Arthropathy of the Ankle
Conditions: Hemophilia A·Matched via name phrase
- NCT06145373·RECRUITING·A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Conditions: Hemophilia A·Matched via name phrase
- NCT07452575·NOT YET RECRUITING·3D Ultrasound in Hemophilic Ankles
Conditions: Hemophilia·Matched via name phrase
- NCT07421154·NOT YET RECRUITING·Study of a Smart Sharps Disposal Device in Patients With Hemophilia
Conditions: Hemophilia A and B·Matched via name phrase
- NCT07719647·NOT YET RECRUITING·Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)
Conditions: Mild Hemophilia·Matched via name phrase
- NCT07545395·RECRUITING·Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Conditions: Hemophilia A or B·Matched via name phrase
- NCT07406139·RECRUITING·PCC Treatment for Hemophilia Patients With Inhibitor(2022PCC-A)
Conditions: Hemophilia · Inhibitors·Matched via name phrase
- NCT07200609·NOT YET RECRUITING·The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia
Conditions: Hemophilia A Without Inhibitor·Matched via name phrase
- NCT03217032·RECRUITING·Lentiviral FVIII Gene Therapy
Conditions: Hemophilia A·Matched via name phrase
- NCT07259356·ENROLLING BY INVITATION·Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia
Conditions: Hemophilia·Matched via name phrase
- NCT07416526·RECRUITING·A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Conditions: Hemophilia A·Matched via name phrase
- NCT07285460·RECRUITING·A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Conditions: Hemophilia·Matched via name phrase
- NCT07226206·RECRUITING·A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Conditions: Hemophilia A·Matched via name phrase
- NCT06864975·RECRUITING·Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
Conditions: Hemophilia a with Inhibitor·Matched via name phrase
- NCT04728841·RECRUITING·Gene Therapy for Chinese Hemophilia A
Conditions: Hemophilia A · Gene Therapy·Matched via name phrase
Observational and natural-history studies
76 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06008938·RECRUITING·An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Conditions: Hemophilia B·Matched via name + MeSH
- NCT06820515·RECRUITING·ATHNdataset Registry
Conditions: Hemophilia · Thrombosis · Hemophilia A · Hemophilia B·Matched via name + MeSH
- NCT03327779·RECRUITING·World Bleeding Disorders Registry
Conditions: Hemophilia A · Hemophilia B · Von Willebrand Diseases·Matched via name + MeSH
- NCT05962398·ENROLLING BY INVITATION·Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Conditions: Hemophilia B·Matched via name + MeSH
- NCT05932914·NOT YET RECRUITING·Liver Biopsy Following Gene Therapy For Hemophilia
Conditions: Hemophilia A · Hemophilia B·Matched via name + MeSH
- NCT06727669·RECRUITING·Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Conditions: Immune Thrombocytopenia · Thrombotic Thrombocytopenic Purpura · Hemophilia A, Acquired · Disseminated Intravascular Coagulation·Matched via name + MeSH
- NCT04398628·RECRUITING·ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Conditions: Hematologic Disorder · Bleeding Disorder · Connective Tissue Disorder · Hemophilia·Matched via name phrase
- NCT02979119·RECRUITING·The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Conditions: Factor VIII Deficiency · Factor IX Deficiency·Matched via name phrase
- NCT06809972·RECRUITING·Synovial Proliferation on Routine Ultrasound: Active or Inactive?
Conditions: Haemophilia · Hemophilia A · Hemophilia B·Matched via name + MeSH
- NCT06147414·RECRUITING·Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Conditions: Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including · Sickle Cell Disease · Cystic Fibrosis · Fragile X Syndrome·Matched via name + MeSH
- NCT04645199·RECRUITING·National Longitudinal Cohort of Hematological Diseases
Conditions: Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia · Hemophilia A·Matched via name + MeSH
- NCT02912143·RECRUITING·German Pediatric Hemophilia Research Database
Conditions: Hemophilia A · Hemophilia B · Children · Drug Specific Antibodies·Matched via name + MeSH
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hemophilia B" OR "Congenital F9 deficiency" OR "Congenital factor IX deficiency" OR "Christmas disease" OR "congenital factor IX disorder" OR "factor IX deficiency" OR "haemophilia b, X-linked recessive" OR "haemophilia type B" OR "hemophilia b, X-linked recessive" OR "hemophilia type B" OR "hereditary Factor IX deficiency" OR "hereditary Factor IX deficiency disease"
MeSH descriptor terms unioned into the query: Hemophilia B
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hemophilia B" OR "Congenital F9 deficiency" OR "Congenital factor IX deficiency" OR "Christmas disease" OR "congenital factor IX disorder" OR "factor IX deficiency" OR "haemophilia b, X-linked recessive" OR "haemophilia type B" OR "hemophilia b, X-linked recessive" OR "hemophilia type B" OR "hereditary Factor IX deficiency" OR "hereditary Factor IX deficiency disease" OR "F9"
Recall-expansion terms: F9
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 120 interventional · 76 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemophilia"
Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:39:21.727Z
